Gefitinib versus erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Nan Fang yi ke da xue xue bao= Journal of Southern …, 2015 - europepmc.org
Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …
被引用次数：18 相关文章

Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Y XIE, JZ LIANG, N SU - Journal of Southern Medical …, 2015 - pesquisa.bvsalud.org
ABSTRACT< p>< b> OBJECTIVE</b> To compare the efficacy of the erlotinib versus
gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive …

[引用][C] Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

Y Xie, J Liang, SU Ning - Journal of Southern Medical …, 2015 - wprim.whocc.org.cn
Western Pacific Region Index Medicus 中文 | English Western Pacific Region Index
Medicus Home | Help | Contact Return Gefitinib versus Erlotinib as first-line treatment for …

Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Y Xie, JZ Liang, N Su - 2015 - pubmed.ncbi.nlm.nih.gov
Objective To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of
patients with advanced EGFR mutation-positive NSCLC. Methods Fifty patients with …